



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 19-024/S-015

B.Braun Medical Inc.  
2525 McGaw Avenue  
P.O.Box 19791  
Irvine, CA 92623-9791

Attention: Jeanne Lanahan  
Manager, regulatory Affairs

Dear Ms. Lanahan:

Please refer to your supplemental new drug application dated November 14, 2002, received November 15, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Physiolyte (physiological irrigating solution) in Plastic Container.

We acknowledge receipt of your submission dated August 14, 2003, which constituted a complete response to our June 3, 2003, action letter.

This supplemental new drug application provides for a newly developed package insert and revised immediate container label.

We have completed the review of this application, as amended, and it is approved effective on the date of this letter.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kim Compton, Regulatory Project Manager, at (301) 827-7410.

Sincerely,

{See appended electronic signature page}

Bob Rappaport, M.D.  
Director  
Division of Anesthetic, Critical Care,  
and Addiction Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Bob Rappaport  
10/22/03 10:45:24 AM